This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dorner F., Scriba M., Weil R.: Interferon: Evidence for its glyco-protein nature. Proc. Natl. Acad. Sci. USA, 1973; 70: 1,981–1,985DornerF.ScribaM.WeilR.Interferon: Evidence for its glyco-protein nature1973701,9811,98510.1073/pnas.70.7.1981Search in Google Scholar
Isaacs A., Lindenmann J.: Virus interference. I. The Interferon. Proc. R. Soc. Lond. B Biol. Sci., 1957; 147: 258–267IsaacsA.LindenmannJ.Virus interference195714725826710.1098/rspb.1957.0048Search in Google Scholar
Interferon nomenclature. Nature, 1980; 286: 110Interferon nomenclature198028611010.1038/286110a0Search in Google Scholar
Havell E.A., Berman B., Ogburn C.A., Berg K., Paucker K., Vilcek J.: Two antigenically distinct species of human interferon. Proc. Natl. Acad. Sci. USA, 1975; 72: 2185–2187HavellE.A.BermanB.OgburnC.A.BergK.PauckerK.VilcekJ.Two antigenically distinct species of human interferon1975722185218710.1073/pnas.72.6.2185Search in Google Scholar
Wheelock E.F.: Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science, 1965; 149: 310–311WheelockE.F.Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin196514931031110.1126/science.149.3681.310Search in Google Scholar
Taniguchi T., Mantei N., Schwarzstein M., Nagata S., Muramatsu M., Weissmann C.: Human leukocyte and fibroblast interferons are structurally related. Nature, 1980; 285: 547–549TaniguchiT.ManteiN.SchwarzsteinM.NagataS.MuramatsuM.WeissmannC.Human leukocyte and fibroblast interferons are structurally related198028554754910.1038/285547a0Search in Google Scholar
Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., Langer J.A., Sheikh F., Dickensheets H., Donnelly R.P.: IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol., 2003; 4: 69–77KotenkoS.V.GallagherG.BaurinV.V.Lewis-AntesA.ShenM.ShahN.K.LangerJ.A.SheikhF.DickensheetsH.DonnellyR.P.IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex20034697710.1038/ni875Search in Google Scholar
Uddin S., Majchrzak B., Woodson J., Arunkumar P., Alsayed Y., Pine R., Young P.R., Fish E.N., Platanias L.C.: Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem., 1999; 274: 30,127–30,131UddinS.MajchrzakB.WoodsonJ.ArunkumarP.AlsayedY.PineR.YoungP.R.FishE.N.PlataniasL.C.Activation of the p38 mitogen-activated protein kinase by type I interferons199927430,12730,13110.1074/jbc.274.42.30127Search in Google Scholar
Darnell J.E. Jr., Kerr I.M., Stark G.R.: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994; 264: 1,415–1,421DarnellJ.E. Jr.KerrI.M.StarkG.R.Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins19942641,4151,42110.1126/science.8197455Search in Google Scholar
Colamonici O.R., D’alessandrot F., Diaz M.O., Gregory S.A., Neckerst L.M., Nordant R.: Characterization of three monoclonal antibodies that recognize the interferon α2 receptor. Proc. Natl. Acad. Sci. USA, 1990; 87: 7,230–7,234ColamoniciO.R.D’alessandrotF.DiazM.O.GregoryS.A.NeckerstL.M.NordantR.Characterization of three monoclonal antibodies that recognize the interferon α2 receptor1990877,2307,23410.1073/pnas.87.18.7230Search in Google Scholar
Colamonici O.R., Domanski P.: Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. J. Biol. Chem., 1993; 268: 10,895–10,899ColamoniciO.R.DomanskiP.Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21199326810,89510,89910.1016/S0021-9258(18)82069-5Search in Google Scholar
Colamonici O.R., Uyttendaelen H., Domanski P., Yan H., Krolewski J.J.: p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically associated with an interferon-alpha receptor. J. Biol. Chem., 1994; 269: 3,518–3,522ColamoniciO.R.UyttendaelenH.DomanskiP.YanH.KrolewskiJ.J.p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically associated with an interferon-alpha receptor19942693,5183,52210.1016/S0021-9258(17)41893-XSearch in Google Scholar
Colamonici O., Yan H., Domanski P., Handa R., Smalley D., Mullersman J., Witte M., Krishnan K., Krolewski J.J.: Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol. Cell. Biol., 1994; 14: 8,133–8,142ColamoniciO.YanH.DomanskiP.HandaR.SmalleyD.MullersmanJ.WitteM.KrishnanK.KrolewskiJ.J.Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase1994148,1338,14210.1128/mcb.14.12.8133-8142.1994Search in Google Scholar
Domanski P., Fish E., Nadeau O.W., Witte M., Platanias L.C., Yan H., Krolewski J.J., Pitha P., Colamonici O.R.: A region of the β subunit of the interferon α receptor different from Box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state. J. Biol. Chem., 1997; 272: 26,388–26,393DomanskiP.FishE.NadeauO.W.WitteM.PlataniasL.C.YanH.KrolewskiJ.J.PithaP.ColamoniciO.R.A region of the β subunit of the interferon α receptor different from Box 1 interacts with Jak1 and is sufficient to activate the Jak-Stat pathway and induce an antiviral state199727226,38826,39310.1074/jbc.272.42.26388Search in Google Scholar
Novick D., Cohen B., Rubinstein M.: The human interferon α/β receptor: Characterization and molecular cloning. Cell, 1994; 77: 391–400NovickD.CohenB.RubinsteinM.The human interferon α/β receptor: Characterization and molecular cloning19947739140010.1016/1043-4666(94)90174-0Search in Google Scholar
Yan H., Krishnan K., Greenlund A.C., Gupta S., Lim J.T., Schreiber R.D., Schindler C.W., Krolewski J.J.: Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J., 1996; 15: 1,064–1,074YanH.KrishnanK.GreenlundA.C.GuptaS.LimJ.T.SchreiberR.D.SchindlerC.W.KrolewskiJ.J.Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein1996151,0641,07410.1002/j.1460-2075.1996.tb00444.xSearch in Google Scholar
Gauzzi M.C., Velazquez L., McKendry R., Mogensen K.E., Fellous M., Pellegrini S.: Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem., 1996; 271: 20,494–20,500GauzziM.C.VelazquezL.McKendryR.MogensenK.E.FellousM.PellegriniS.Interferon-α-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase199627120,49420,50010.1074/jbc.271.34.20494Search in Google Scholar
Shuai K., Horvath C.M., Tsai Huang L.H., Qureshi S.A., Cowburn D., Darnell J.E.Jr.: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 1994; 76: 821–828ShuaiK.HorvathC.M.TsaiHuang L.H.QureshiS.A.CowburnD.DarnellJ.E.Jr.Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions19947682182810.1016/0092-8674(94)90357-3Search in Google Scholar
Yang C.H., Shi W., Basu L., Murti A., Constantinescu S.N., Blatt L., Croze E., Mullersman J.E., Pfeffer L.M.: Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J. Biol. Chem., 1996; 271: 8,057–8,061YangC.H.ShiW.BasuL.MurtiA.ConstantinescuS.N.BlattL.CrozeE.MullersmanJ.E.PfefferL.M.Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor19962718,0578,06110.1074/jbc.271.14.80578626489Search in Google Scholar
Nguyen K.B., Watford W.T., Salomon R., Hofmann S.R., Pien G.C., Morinobu A., Gadina M., O’Shea J.J., Biron C.A.: Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection. Science, 2002; 297: 2,063–2,066NguyenK.B.WatfordW.T.SalomonR.HofmannS.R.PienG.C.MorinobuA.GadinaM.O’SheaJ.J.BironC.A.Critical role for STAT4 activation by type 1 interferons in the interferon-γ response to viral infection20022972,0632,06610.1126/science.107490012242445Search in Google Scholar
Meinke A., Barahmand-Pour F., Wöhrl S., Stoiber D., Decker T.: Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol. Cell. Biol., 1996; 16: 6,937–6,944MeinkeA.Barahmand-PourF.WöhrlS.StoiberD.DeckerT.Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons1996166,9376,94410.1128/MCB.16.12.69372316978943349Search in Google Scholar
Gupta S., Jiang M., Pernis A.B.: IFN-α activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J. Immunol., 1999; 163: 3,834–3,841GuptaS.JiangM.PernisA.B.IFN-α activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells19991633,8343,84110.4049/jimmunol.163.7.3834Search in Google Scholar
Platanias L.C., Sweet M.E.: Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells. J. Biol. Chem., 1994; 269: 3,143–3,146PlataniasL.C.SweetM.E.Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells19942693,1433,14610.1016/S0021-9258(17)41839-4Search in Google Scholar
Uddin S., Sweet M., Colmonici O.R., Krolewski J.J., Platanias L.C.: The vav proto-oncogene product (p95vav interacts with the Tyk-2 protein tyrosine kinase. FEBS Lett., 1997; 403: 31–34UddinS.SweetM.ColmoniciO.R.KrolewskiJ.J.PlataniasL.C.The vav proto-oncogene product (p95vav interacts with the Tyk-2 protein tyrosine kinase1997403313410.1016/S0014-5793(97)00023-9Search in Google Scholar
Uddin S., Lekmine F., Sharma N., Majchrzak B., Mayer I., Young P.R., Bokoch G.M., Fish E.N., Platanias L.C.: The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon α-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem., 2000; 275: 27,634–27,640UddinS.LekmineF.SharmaN.MajchrzakB.MayerI.YoungP.R.BokochG.M.FishE.N.PlataniasL.C.The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon α-dependent transcriptional activation but not serine phosphorylation of Stat proteins200027527,63427,64010.1074/jbc.M003170200Search in Google Scholar
Murphy L.O., Smith S., Chen R.H., Fingar D.C., Blenis J.: Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol., 2002; 4: 556–564MurphyL.O.SmithS.ChenR.H.FingarD.C.BlenisJ.Molecular interpretation of ERK signal duration by immediate early gene products2002455656410.1038/ncb822Search in Google Scholar
Yang B.S., Hauser C.A., Henkel G., Colman M.S., Van Beveren C., Stacey K.J., Hume D.A., Maki R.A., Ostrowski M.C.: Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol. Cell. Biol., 1996; 16: 538–547YangB.S.HauserC.A.HenkelG.ColmanM.S.VanBeveren C.StaceyK.J.HumeD.A.MakiR.A.OstrowskiM.C.Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets219961653854710.1128/MCB.16.2.538Search in Google Scholar
Gille H., Sharrocks A.D., Shaw P.E.: Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature, 1992; 358: 414–417GilleH.SharrocksA.D.ShawP.E.Phosphorylation of transcription factor p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter199235841441710.1038/358414a0Search in Google Scholar
Milne D.M., Campbell D.G., Caudwell F.B., Meek D.W.: Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J. Biol. Chem. 1994; 269: 9,253–9,260MilneD.M.CampbellD.G.CaudwellF.B.MeekD.W.Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases19942699,2539,26010.1016/S0021-9258(17)37101-6Search in Google Scholar
Hervas-Stubbs S., Perez-Gracia J.L., Rouzaut A., Sanmamed M.F., Le Bon A., Melero I.: Direct effects of type I interferons on cells of the immune system. Clin. Cancer Res., 2011; 17: 2,619– 2,627Hervas-StubbsS.Perez-GraciaJ.L.RouzautA.SanmamedM.F.Le BonA.MeleroI.Direct effects of type I interferons on cells of the immune system2011172,6192,62710.1158/1078-0432.CCR-10-1114Search in Google Scholar
Backer J.M., Schroeder G.G., Kahn C.R., Myers M.G. Jr, Wilden P.A., Cahill D.A., White M.F.: Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation. J. Biol. Chem., 1992; 267: 1,367–1,374BackerJ.M.SchroederG.G.KahnC.R.MyersM.G. JrWildenP.A.CahillD.A.WhiteM.F.Insulin stimulation of phosphatidylinositol 3-kinase activity maps to insulin receptor regions required for endogenous substrate phosphorylation19922671,3671,37410.1016/S0021-9258(18)48440-2Search in Google Scholar
Uddin S., Yenush L., Sun X.J., Sweet M.E., White M.F., Platanias L.C.: Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3’-kinase. J. Biol. Chem., 1995; 270: 15,938–15,941UddinS.YenushL.SunX.J.SweetM.E.WhiteM.F.PlataniasL.C.Interferon-α engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3’-kinase199527015,93815,94110.1074/jbc.270.27.159387608146Search in Google Scholar
Pfeffer L.M., Mullersman J.E., Pfeffer S.R., Murti A., Shi W., Yang C.H.: STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science, 1997; 276: 1,418–1,420PfefferL.M.MullersmanJ.E.PfefferS.R.MurtiA.ShiW.YangC.H.STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor19972761,4181,42010.1126/science.276.5317.1418Search in Google Scholar
Kaur S., Sassano A., Dolniak B., Joshi S., Majchrzak-Kita B., Baker D.P., Hay N., Fish E.N., Platanias L.C.: Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl. Acad. Sci. USA, 2008; 105: 4,808–4,813KaurS.SassanoA.DolniakB.JoshiS.Majchrzak-KitaB.BakerD.P.HayN.FishE.N.PlataniasL.C.Role of the Akt pathway in mRNA translation of interferon-stimulated genes20081054,8084,81310.1073/pnas.0710907105Search in Google Scholar
Yang C.H., Murti A., Pfeffer S.R., Basu L., Kim J.G., Pfeffer L.M.: IFN α/β promotes cell survival by activating NF-κB. Proc. Natl. Acad. Sci. USA, 2000; 97: 13,631–13,636YangC.H.MurtiA.PfefferS.R.BasuL.KimJ.G.PfefferL.M.IFN α/β promotes cell survival by activating NF-κB20009713,63113,63610.1073/pnas.250477397Search in Google Scholar
Lekmine F., Uddin S., Sassano A., Parmar S., Brachmann S.M., Majchrzak B., Sonenberg N., Hay N., Fish E.N., Platanias L.C.: Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem., 2003; 278: 27,772–27,780LekmineF.UddinS.SassanoA.ParmarS.BrachmannS.M.MajchrzakB.SonenbergN.HayN.FishE.N.PlataniasL.C.Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons200327827,77227,78010.1074/jbc.M301364200Search in Google Scholar
Yang C.H., Murti A., Pfeffer L.M.: Interferon induces NF-κB-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-κB activation to promote cell survival. J. Biol. Chem., 2005; 280: 31,530–31,536YangC.H.MurtiA.PfefferL.M.Interferon induces NF-κB-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-κB activation to promote cell survival200528031,53031,53610.1074/jbc.M503120200Search in Google Scholar
Bramanti P., Sessa E., Rifici C., D’Aleo G., Floridia D., Di Bella P., Lublin F.: Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology, 1998; 51: 1,720–1,723BramantiP.SessaE.RificiC.D’AleoG.FloridiaD.DiBella P.LublinF.Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b1998511,7201,72310.1212/WNL.51.6.1720Search in Google Scholar
Harbo H.F., Gold R., Tintoré M.: Sex and gender issues in multiple sclerosis. Ther. Adv. Neurol. Disord., 2013; 6: 237–248HarboH.F.GoldR.TintoréM.Sex and gender issues in multiple sclerosis2013623724810.1177/1756285613488434Search in Google Scholar
Bach M.A., Phan-Dinh-Tuy F., Tournier E., Chatenoud L., Bach J.F., Martin C., Degos J.D.: Deficit of suppressor T cells in active multiple sclerosis. Lancet, 1980; 2: 1,221–1,223BachM.A.Phan-Dinh-TuyF.TournierE.ChatenoudL.BachJ.F.MartinC.DegosJ.D.Deficit of suppressor T cells in active multiple sclerosis198021,2211,22310.1016/S0140-6736(80)92480-0Search in Google Scholar
Booss J., Esiri M.M., Tourtellotte W.W., Mason D.Y.: Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J. Neurol. Sci., 1983; 62: 219–232BoossJ.EsiriM.M.TourtellotteW.W.MasonD.Y.Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis19836221923210.1016/0022-510X(83)90201-0Search in Google Scholar
Rose L.M., Ginsberg A.H., Rothstein T.L., Ledbetter J.A., Clark E.A.: Selective loss of a subset of T helper cells in active multiple sclerosis. Proc. Natl. Acad. Sci. USA, 1985; 82: 7,389–7,393RoseL.M.GinsbergA.H.RothsteinT.L.LedbetterJ.A.ClarkE.A.Selective loss of a subset of T helper cells in active multiple sclerosis1985827,3897,39310.1073/pnas.82.21.73893913502932738Search in Google Scholar
Esiri M.M.: Multiple sclerosis: A quantitative and qualitative study of immunoglobulin‐containing cells in the central nervous system. Neuropathol. Appl. Neurobiol., 1980; 6: 9–21EsiriM.M.Multiple sclerosis: A quantitative and qualitative study of immunoglobulin‐containing cells in the central nervous system1980692110.1111/j.1365-2990.1980.tb00199.xSearch in Google Scholar
Ohguro H., Chiba S., Igarashi Y., Matsumoto H., Akino T., Palczewski K.: Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients. Proc. Natl. Acad. Sci. USA, 1993; 90: 3,241–3,245OhguroH.ChibaS.IgarashiY.MatsumotoH.AkinoT.PalczewskiK.Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients1993903,2413,24510.1073/pnas.90.8.3241Search in Google Scholar
Shi Y., Feng Y., Kang J., Liu C., Li Z., Li D., Cao W., Qiu J., Guo Z., Bi E., et al.: Critical regulation of CD4+ T cell survival and autoimmunity by β-arrestin 1. Nat. Immunol., 2007; 8: 817–824ShiY.FengY.KangJ.LiuC.LiZ.LiD.CaoW.QiuJ.GuoZ.BiE.et alCritical regulation of CD4+ T cell survival and autoimmunity by β-arrestin 12007881782410.1038/ni1489Search in Google Scholar
Millar J.H., Allison R.S.: Familial incidence of disseminated sclerosis in Northern Ireland. Ulster Med. J., 1954; 23: 29–92MillarJ.H.AllisonR.S.Familial incidence of disseminated sclerosis in Northern Ireland1954232992Search in Google Scholar
Müller R.: Genetic aspects of multiple sclerosis. AMA Arch. Neur. Psychiatry, 1953; 70: 733–740MüllerR.Genetic aspects of multiple sclerosis19537073374010.1001/archneurpsyc.1953.02320360048005Search in Google Scholar
Pratt R.T., Compston N.D., McAlpine D.: The familial incidence of disseminated sclerosis and its significance. Brain, 1951; 74: 191–232PrattR.T.CompstonN.D.McAlpineD.The familial incidence of disseminated sclerosis and its significance19517419123210.1093/brain/74.2.191Search in Google Scholar
Goldberg P., Fleming M.C., Picard E.H.: Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med. Hypotheses, 1986; 21: 193–200GoldbergP.FlemingM.C.PicardE.H.Multiple sclerosis: Decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D19862119320010.1016/0306-9877(86)90010-1Search in Google Scholar
McMichael A.J., Hall A.J.: Does immunosuppressive ultraviolet radiation explain the latitude gradient for multiple sclerosis? Epidemiology, 1997; 8: 642–645McMichaelA.J.HallA.J.Does immunosuppressive ultraviolet radiation explain the latitude gradient for multiple sclerosis?1997864264510.1097/00001648-199711000-00009Search in Google Scholar
Nikoskelainen J., Panelius M., Salmi A.: E.B. virus and multiple sclerosis. Br. Med. J., 1972; 4: 111NikoskelainenJ.PaneliusM.SalmiA.E.B. virus and multiple sclerosis1972411110.1136/bmj.4.5832.11117862424342670Search in Google Scholar
Emre M., de Decker K.: Effects of cigarette smoking on motor functions in patients with multiple sclerosis. Arch. Neurol., 1992; 49: 1,243–1,247EmreM.de DeckerK.Effects of cigarette smoking on motor functions in patients with multiple sclerosis1992491,2431,24710.1001/archneur.1992.005303600410151449402Search in Google Scholar
Munger K.L., Chitnis T., Ascherio A.: Body size and risk of MS in two cohorts of US women. Neurology, 2009; 73: 1,543–1,550MungerK.L.ChitnisT.AscherioA.Body size and risk of MS in two cohorts of US women2009731,5431,55010.1212/WNL.0b013e3181c0d6e0277707419901245Search in Google Scholar
Compston A., Coles A.: Multiple sclerosis. Lancet, 2002; 359: 1,221-1,231CompstonA.ColesA.Multiple sclerosis20023591,2211,23110.1016/S0140-6736(02)08220-XSearch in Google Scholar
Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 1995; 45: 1,268–1,276JohnsonK.P.BrooksB.R.CohenJ.A.FordC.C.GoldsteinJ.LisakR.P.MyersL.W.PanitchH.S.RoseJ.W.SchifferR.B.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group1995451,2681,27610.1212/WNL.45.7.1268Search in Google Scholar
Hartung H.P., Consette R., König N., Kwiecinski H., Guseo A., Morrissey S.P., Krapf H., Zwingers T., Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet, 2002; 360: 2,018–2,025HartungH.P.ConsetteR.KönigN.KwiecinskiH.GuseoA.MorrisseyS.P.KrapfH.ZwingersT.Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial20023602,0182,02510.1016/S0140-6736(02)12023-XSearch in Google Scholar
Polman C.H., O’Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., 2006; 354: 899–910PolmanC.H.O’ConnorP.W.HavrdovaE.HutchinsonM.KapposL.MillerD.H.PhillipsJ.T.LublinF.D.GiovannoniG.WajgtA.et alA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis200635489991010.1056/NEJMoa044397Search in Google Scholar
Kappos L., Radue E.W., O’Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med., 2010; 362: 387–401KapposL.RadueE.W.O’ConnorP.PolmanC.HohlfeldR.CalabresiP.SelmajK.AgoropoulouC.LeykM.Zhang-AubersonL.et alA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis201036238740110.1056/NEJMoa0909494Search in Google Scholar
Gyódi E., Benczur M., Pálffy G., Tálas M., Petrányi G., Földes I., Hollán S.R.: Association between HLA B7, DR2 and dysfunction of natural and antibody-mediated cytotoxicity without connection with the deficient interferon production in multiple sclerosis. Hum. Immunol., 1982; 4: 209–217GyódiE.BenczurM.PálffyG.TálasM.PetrányiG.FöldesI.HollánS.R.Association between HLA B7, DR2 and dysfunction of natural and antibody-mediated cytotoxicity without connection with the deficient interferon production in multiple sclerosis1982420921710.1016/0198-8859(82)90036-2Search in Google Scholar
Haahr S., Møller-Larsen A., Pedersen E.: Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group. Clin. Exp. Immunol., 1983; 51: 197–206HaahrS.Møller-LarsenA.PedersenE.Immunological parameters in multiple sclerosis patients with special reference to the herpes virus group198351197206Search in Google Scholar
Maruo Y.: Interferon production and natural killer activity of peripheral blood lymphocytes obtained from patients with multiple sclerosis. Hokkaido Igaku Zasshi, 1988; 63: 521–533MaruoY.Interferon production and natural killer activity of peripheral blood lymphocytes obtained from patients with multiple sclerosis198863521533Search in Google Scholar
Feng X., Petraglia A.L., Chen M., Byskosh P.V., Boos M.D., Reder A.T.: Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J. Neuroimmunol., 2002; 129: 205–215FengX.PetragliaA.L.ChenM.ByskoshP.V.BoosM.D.RederA.T.Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1200212920521510.1016/S0165-5728(02)00182-0Search in Google Scholar
Whitney L.W., Becker K.G., Tresser N.J., Caballero-Ramos C.I., Munson P.J., Prabhu V.V., Trent J.M., McFarland H.F., Biddison W.E.: Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann. Neurol., 1999; 46: 425–428WhitneyL.W.BeckerK.G.TresserN.J.Caballero-RamosC.I.MunsonP.J.PrabhuV.V.TrentJ.M.McFarlandH.F.BiddisonW.E.Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays19994642542810.1002/1531-8249(199909)46:3<425::AID-ANA22>3.0.CO;2-OSearch in Google Scholar
Hertzog P.J., Wright A., Harris G., Linnane A.W., Mackay I.R.: Intermittent interferonemia and interferon responses in multiple sclerosis. Clin. Immunol. Immunopathol., 1991; 58: 18–32HertzogP.J.WrightA.HarrisG.LinnaneA.W.MackayI.R.Intermittent interferonemia and interferon responses in multiple sclerosis199158183210.1016/0090-1229(91)90145-ZSearch in Google Scholar
Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L.: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 1986; 136: 2,348–2,357MosmannT.R.CherwinskiH.BondM.W.GiedlinM.A.CoffmanR.L.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins19861362,3482,35710.4049/jimmunol.136.7.2348Search in Google Scholar
Suzuki Y., Orellana M.A., Schreiber R.D., Remington J.S.: Interferon-gamma: The major mediator of resistance against Toxoplasma gondii. Science, 1988; 240: 516–518SuzukiY.OrellanaM.A.SchreiberR.D.RemingtonJ.S.Interferon-gamma: The major mediator of resistance against Toxoplasma gondii198824051651810.1126/science.3128869Search in Google Scholar
Selmaj K., Raine C.S., Cannella B., Brosnan C.F.: Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest., 1991; 87: 949–954SelmajK.RaineC.S.CannellaB.BrosnanC.F.Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions19918794995410.1172/JCI1151023298861999503Search in Google Scholar
Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., et al.: Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med., 2007; 13: 843– 850DarrahP.A.PatelD.T.De LucaP.M.LindsayR.W.DaveyD.F.FlynnB.J.HoffS.T.AndersenP.ReedS.G.MorrisS.L.et alMultifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major20071384385010.1038/nm159217558415Search in Google Scholar
Golaz J., Steck A., Moretta L.: Activated T lymphocytes in patients with multiple sclerosis. Neurology, 1983; 33:1,371–1,373GolazJ.SteckA.MorettaL.Activated T lymphocytes in patients with multiple sclerosis1983331,3711,37310.1212/WNL.33.10.13716193457Search in Google Scholar
Hojati Z., Kay M., Dehghanian F.: Chapter 15—Mechanism of action of interferon beta in treatment of multiple sclerosis. In: Multiple Sclerosis: A Mechanistic View, eds.: A. Minagar. Academic Press, Cambridge (MA) 2016, 365–392HojatiZ.KayM.DehghanianF.Chapter 15—Mechanism of action of interferon beta in treatment of multiple sclerosisInedsMinagarA.Academic PressCambridge (MA)201636539210.1016/B978-0-12-800763-1.00015-4Search in Google Scholar
Yen J.H., Ganea D.: Interferon β induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. Blood, 2009; 114: 1,344–1,354YenJ.H.GaneaD.Interferon β induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation20091141,3441,35410.1182/blood-2008-12-196592272741219531658Search in Google Scholar
Paterka M., Siffrin V., Voss J.O., Werr J., Hoppmann N., Gollan R., Belikan P., Bruttger J., Birkenstock J., Jung S., et al.: Gatekeeper role of brain antigen-presenting CD11c+ cells in neuroinflammation. EMBO J., 2016; 35: 89–101PaterkaM.SiffrinV.VossJ.O.WerrJ.HoppmannN.GollanR.BelikanP.BruttgerJ.BirkenstockJ.JungS.et alGatekeeper role of brain antigen-presenting CD11c+ cells in neuroinflammation2016358910110.15252/embj.201591488471800526612827Search in Google Scholar
Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B.: Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med., 2005; 11: 328–334GreterM.HeppnerF.L.LemosM.P.OdermattB.M.GoebelsN.LauferT.NoelleR.J.BecherB.Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis20051132833410.1038/nm119715735653Search in Google Scholar
Zozulya A.L., Ortler S., Lee J.E., Weidenfeller C., Sandor M., Wiendl H., Fabry Z.: Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J. Neurosci., 2009; 29: 140–152ZozulyaA.L.OrtlerS.LeeJ.E.WeidenfellerC.SandorM.WiendlH.FabryZ.Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS20092914015210.1523/JNEUROSCI.2199-08.2009294209119129392Search in Google Scholar
Bailey S.L., Schreiner B., McMahon E.J., Miller S.D.: CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ TH-17 cells in relapsing EAE. Nat. Immunol., 2007; 8: 172–180BaileyS.L.SchreinerB.McMahonE.J.MillerS.D.CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ TH-17 cells in relapsing EAE2007817218010.1038/ni143017206145Search in Google Scholar
Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., Basham B., Smith K., Chen T., Morel F., et al.: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol., 2007; 8: 950–957WilsonN.J.BonifaceK.ChanJ.R.McKenzieB.S.BlumenscheinW.M.MattsonJ.D.BashamB.SmithK.ChenT.MorelF.et alDevelopment, cytokine profile and function of human interleukin 17-producing helper T cells2007895095710.1038/ni149717676044Search in Google Scholar
Bettelli E., Oukka M., Kuchroo V.K.: TH-17 cells in the circle of immunity and autoimmunity. Nat. Immunol., 2007; 8: 345–350BettelliE.OukkaM.KuchrooV.K.TH-17 cells in the circle of immunity and autoimmunity2007834535010.1038/ni0407-345Search in Google Scholar
Matusevicius D., Kivisäkk P., He B., Kostulas N., Õzenci V., Fredrikson S., Link H.: Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler., 1999; 5: 101–104MatuseviciusD.KivisäkkP.HeB.KostulasN.ÕzenciV.FredriksonS.LinkH.Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis1999510110410.1177/135245859900500206Search in Google Scholar
Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al.: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med., 2002; 8: 500–508LockC.HermansG.PedottiR.BrendolanA.SchadtE.GarrenH.Langer-GouldA.StroberS.CannellaB.AllardJ.et alGene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis2002850050810.1038/nm0502-500Search in Google Scholar
Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y.: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol., 2006; 177: 566–573KomiyamaY.NakaeS.MatsukiT.NambuA.IshigameH.KakutaS.SudoK.IwakuraY.IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis200617756657310.4049/jimmunol.177.1.566Search in Google Scholar
Sweeney C.M., Lonergan R., Basdeo S.A., Kinsella K., Dungan L.S., Higgins S.C., Kelly P.J., Costelloe L., Tubridy N., Mills K.H., et al.: IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun., 2011; 25: 1,170–1,181SweeneyC.M.LonerganR.BasdeoS.A.KinsellaK.DunganL.S.HigginsS.C.KellyP.J.CostelloeL.TubridyN.MillsK.H.et alIL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells2011251,1701,18110.1016/j.bbi.2011.03.007Search in Google Scholar
Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S.: IFN-β inhibits human Th17 cell differentiation. J. Immunol., 2009; 183: 5,418–5,427RamgolamV.S.ShaY.JinJ.ZhangX.Markovic-PleseS.IFN-β inhibits human Th17 cell differentiation20091835,4185,42710.4049/jimmunol.0803227Search in Google Scholar
Yen J.H., Kong W., Ganea D.: IFN-β inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J. Immunol., 2010; 184: 3,478–3,486YenJ.H.KongW.GaneaD.IFN-β inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 920101843,4783,48610.4049/jimmunol.0902542Search in Google Scholar
Gay D., Esiri M.: Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain, 1991; 114: 557–572GayD.EsiriM.Blood-brain barrier damage in acute multiple sclerosis plaques199111455757210.1093/brain/114.1.557Search in Google Scholar
Bolton S.J., Anthony D.C., Perry V.H.: Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience, 1998; 86: 1,245–1,257BoltonS.J.AnthonyD.C.PerryV.H.Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo1998861,2451,25710.1016/S0306-4522(98)00058-XSearch in Google Scholar
Wolburg H., Wolburg-Buchholz K., Kraus J., Rascher-Eggstein G., Liebner S., Hamm S., Duffner F., Grote E.H., Risau W., Engelhardt B.: Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol., 2003; 105: 586–592WolburgH.Wolburg-BuchholzK.KrausJ.Rascher-EggsteinG.LiebnerS.HammS.DuffnerF.GroteE.H.RisauW.EngelhardtB.Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme200310558659210.1007/s00401-003-0688-z12734665Search in Google Scholar
Alvarez J.I., Cayrol R., Prat A.: Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta, 2011; 1812: 252-264AlvarezJ.I.CayrolR.PratA.Disruption of central nervous system barriers in multiple sclerosis2011181225226410.1016/j.bbadis.2010.06.017Search in Google Scholar
Stone A.L., Frank J.A., Albert P.S., Bash C., Smith M.E., Maloni H., McFarland H.F.: The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann. Neurol., 1995; 37: 611–619StoneA.L.FrankJ.A.AlbertP.S.BashC.SmithM.E.MaloniH.McFarlandH.F.The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis19953761161910.1002/ana.410370511Search in Google Scholar
Jacobs L., O’Malley J., Freeman A., Ekes R.: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science, 1981; 214: 1,026–1,028JacobsL.O’MalleyJ.FreemanA.EkesR.Intrathecal interferon reduces exacerbations of multiple sclerosis19812141,0261,02810.1126/science.6171035Search in Google Scholar
The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993; 43: 655–661The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial19934365566110.1212/WNL.43.4.655Search in Google Scholar
Paty D.W., Li D.K.: Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 1993; 43: 662–667PatyD.W.LiD.K.Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group19934366266710.1212/WNL.43.4.662Search in Google Scholar
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology, 1995; 45: 1,277–1,285The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group1995451,2771,28510.1212/WNL.45.7.1277Search in Google Scholar
Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol., 1996; 39: 285–294JacobsL.D.CookfairD.L.RudickR.A.HerndonR.M.RichertJ.R.SalazarA.M.FischerJ.S.GoodkinD.E.GrangerC.V.SimonJ.H.et alIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)19963928529410.1002/ana.410390304Search in Google Scholar
Jacobs L.D., Cookfair D.L., Rudic R.A., Herndon R.M., Richerf J.R., Salazar A.M., Fischef J.S., Goodkin D.E., Grangef C.V., Simon J.H., et al.: A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult. Scler., 1995; 1: 118–135JacobsL.D.CookfairD.L.RudicR.A.HerndonR.M.RicherfJ.R.SalazarA.M.FischefJ.S.GoodkinD.E.GrangefC.V.SimonJ.H.et alA phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: Design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG)1995111813510.1177/135245859500100210Search in Google Scholar
Li D.K., Paty D.W., UBC MS/MRI Analysis Research Group, PRISMS Study Group: Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-β1a subcutaneously in multiple sclerosis. Ann. Neurol., 1999; 46: 197–206LiD.K.PatyD.W.UBC MS/MRI Analysis Research Group, PRISMS Study Group: Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-β1a subcutaneously in multiple sclerosis19994619720610.1002/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-PSearch in Google Scholar
Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Granger C.V., Simon J.H., et al.: Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology, 1997; 49: 358–363RudickR.A.GoodkinD.E.JacobsL.D.CookfairD.L.HerndonR.M.RichertJ.R.SalazarA.M.FischerJ.S.GrangerC.V.SimonJ.H.et alImpact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group19974935836310.1212/WNL.49.2.358Search in Google Scholar
Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al.: Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol., 1996; 43: 79–87SimonJ.H.JacobsL.D.CampionM.WendeK.SimonianN.CookfairD.L.RudickR.A.HerndonR.M.RichertJ.R.SalazarA.M.et alMagnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group199643798710.1002/ana.410430114Search in Google Scholar
Liu C., Blumhardt L.D.: Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J. Neurol. Neurosurg. Psychiatry, 1999; 67: 451–456LiuC.BlumhardtL.D.Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves19996745145610.1136/jnnp.67.4.451Search in Google Scholar
Ebers G.C., PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet, 1998; 352: 1,498–1,504EbersG.C.PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis19983521,4981,50410.1016/S0140-6736(98)03334-0Search in Google Scholar
Walther E.U., Hohlfeld R.: Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology, 1999; 53: 1,622–1,627WaltherE.U.HohlfeldR.Multiple sclerosis: side effects of interferon beta therapy and their management1999531,6221,62710.1212/WNL.53.8.1622Search in Google Scholar
Kaiser L., Fritz R.S., Straus S.E., Gubareva L., Hayden F.G.: Symptom pathogenesis during acute influenza: Interleukin-6 and other cytokine responses. J. Med. Virol., 2001; 64: 262–268KaiserL.FritzR.S.StrausS.E.GubarevaL.HaydenF.G.Symptom pathogenesis during acute influenza: Interleukin-6 and other cytokine responses20016426226810.1002/jmv.1045Search in Google Scholar
Joffe R.T., Lippert G.P., Gray T.A., Sawa G., Horvath Z.: Mood disorders and multiple sclerosis. Arch. Neurol., 1987; 44: 376–378JoffeR.T.LippertG.P.GrayT.A.SawaG.HorvathZ.Mood disorders and multiple sclerosis19874437637810.1001/archneur.1987.00520160018007Search in Google Scholar
WHO. Hepatitis C. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (15.04.2019)HepatitisC.https://www.who.int/news-room/fact-sheets/detail/hepatitis-c15.04.2019Search in Google Scholar
Webster D.P., Klenerman P., Dusheiko G.M.: Hepatitis C. Lancet, 2015; 385: 1,124–1,135WebsterD.P.KlenermanP.DusheikoG.M.Hepatitis C20153851,1241,13510.1016/S0140-6736(14)62401-6Search in Google Scholar
Shirachi R., Shiraishi H., Tateda A., Kikuchi K., Ishida N.: Hepatitis “C” antigen in non-A, non-B post-transfusion hepatitis. Lancet, 1978; 2: 853–856ShirachiR.ShiraishiH.TatedaA.KikuchiK.IshidaN.Hepatitis “C” antigen in non-A, non-B post-transfusion hepatitis1978285385610.1016/S0140-6736(78)91567-2Search in Google Scholar
Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M.: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989; 244: 359–362ChooQ.L.KuoG.WeinerA.J.OverbyL.R.BradleyD.W.HoughtonM.Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome198924435936210.1126/science.25235622523562Search in Google Scholar
Grakoui A., Wychowski C., Lin C., Feinstone S.M., Rice C.M.: Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol., 1993; 67: 1,385–1,395GrakouiA.WychowskiC.LinC.FeinstoneS.M.RiceC.M.Expression and identification of hepatitis C virus polyprotein cleavage products1993671,3851,39510.1128/jvi.67.3.1385-1395.19932375087679746Search in Google Scholar
Lanford R.E., Guerra B., Lee H., Averett D.R., Pfeiffer B., Chavez D., Notvall L., Bigger C.: Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus sub-genomic replicons. J. Virol., 2003; 77: 1,092–1,104LanfordR.E.GuerraB.LeeH.AverettD.R.PfeifferB.ChavezD.NotvallL.BiggerC.Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus sub-genomic replicons2003771,0921,10410.1128/JVI.77.2.1092-1104.2003Search in Google Scholar
Ji X., Cheung R., Cooper S., Li Q., Greenberg H.B., He X.S.: Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology, 2003; 37: 610–621JiX.CheungR.CooperS.LiQ.GreenbergH.B.HeX.S.Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C20033761062110.1053/jhep.2003.50105Search in Google Scholar
Moriishi K., Matsuura Y.: Mechanisms of hepatitis C virus infection. Antivir. Chem. Chemother., 2003; 14: 285–297MoriishiK.MatsuuraY.Mechanisms of hepatitis C virus infection20031428529710.1177/095632020301400601Search in Google Scholar
Wang C., Pflugheber J., Sumpter R.Jr., Sodora D.L., Hui D., Sen G.C., Gale M.Jr: Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol., 2003; 77: 3,898–3,912WangC.PflugheberJ.SumpterRJr.SodoraD.L.HuiD.SenG.C.GaleM.JrAlpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication2003773,8983,91210.1128/JVI.77.7.3898-3912.2003Search in Google Scholar
Schvarcz R., Weiland O., Wejstål R., Norkrans G., Frydén A., Foberg U.: A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies. Scand. J. Infect. Dis., 1989; 21: 617–625SchvarczR.WeilandO.WejstålR.NorkransG.FrydénA.FobergU.A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies19892161762510.3109/00365548909021689Search in Google Scholar
Brillanti S., Garson J., Foli M., Whitby K., Deaville R., Masci C., Miglioli M., Barbara L.: A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology, 1994; 107: 812–817BrillantiS.GarsonJ.FoliM.WhitbyK.DeavilleR.MasciC.MiglioliM.BarbaraL.A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C199410781281710.1016/0016-5085(94)90131-7Search in Google Scholar
Shiffman M.L.: Pegylated interferons: What role will they play in the treatment of chronic hepatitis C? Curr. Gastroenterol. Rep., 2001; 3: 30–37ShiffmanM.L.Pegylated interferons: What role will they play in the treatment of chronic hepatitis C? Curr20013303710.1007/s11901-003-0010-5Search in Google Scholar
Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S., Clement R.P.: A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology, 2000; 32: 647–653GlueP.Rouzier-PanisR.RaffanelC.SaboR.GuptaS.K.SalfiM.JacobsS.ClementR.P.A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C20003264765310.1053/jhep.2000.1666110960463Search in Google Scholar
Maughan A., Ogbuagu O.: Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin. Drug Metab. Toxicol., 2018; 14: 219–227MaughanA.OgbuaguO.Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection20181421922710.1080/17425255.2018.142117329271660Search in Google Scholar
Reichenberg A., Gorman J.M., Dieterich D.T.: Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS, 2005; 19: S174–S178ReichenbergA.GormanJ.M.DieterichD.T.Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study200519S174S17810.1097/01.aids.0000192087.64432.ae16251815Search in Google Scholar
Rentiya Z.S., Wells M., Bae J., Chen K.J., Chao A.N., Turgeon N., Shah S.M., Hanout M.: Interferon-α-induced retinopathy in chronic hepatitis C treatment: Summary, considerations, and recommendations. Graefes Arch. Clin. Exp. Ophthalmol., 2019; 257: 447–452RentiyaZ.S.WellsM.BaeJ.ChenK.J.ChaoA.N.TurgeonN.ShahS.M.HanoutM.Interferon-α-induced retinopathy in chronic hepatitis C treatment: Summary, considerations, and recommendations201925744745210.1007/s00417-018-04209-730547319Search in Google Scholar
Zornitzki T., Malnick S., Lysyy L., Knobler H.: Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J. Gastroenterol., 2015; 21: 233–239ZornitzkiT.MalnickS.LysyyL.KnoblerH.Interferon therapy in hepatitis C leading to chronic type 1 diabetes20152123323910.3748/wjg.v21.i1.233428434025574096Search in Google Scholar